<div id="readability-page-1"><p>Price T Rowe Associates Inc. MD cut its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 17.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 332,020 shares of the company's stock after selling 71,733 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.71% of Pacira BioSciences worth $9,703,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Pacira BioSciences</strong> alerts:</span></p></div><p>A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after buying an additional 14,960 shares in the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Pacira BioSciences by 15.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock worth $70,332,000 after purchasing an additional 285,045 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Pacira BioSciences by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company's stock worth $47,633,000 after purchasing an additional 17,949 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Pacira BioSciences in the fourth quarter worth approximately $40,488,000. Finally, Clearbridge Investments LLC lifted its position in shares of Pacira BioSciences by 2.3% in the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock worth $34,250,000 after purchasing an additional 26,463 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research firms have recently issued reports on PCRX. Royal Bank of Canada reduced their price target on shares of Pacira BioSciences from $42.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Raymond James reduced their price target on shares of Pacira BioSciences from $41.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $43.00 price target on shares of Pacira BioSciences in a research report on Wednesday. HC Wainwright restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Tuesday, July 2nd. Finally, Truist Financial dropped their price objective on Pacira BioSciences from $45.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $41.44.</p><p><b>Check Out Our Latest Research Report on Pacira BioSciences</b></p><h2>Insider Buying and Selling at Pacira BioSciences</h2><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $28.57, for a total transaction of $143,192.84. Following the transaction, the insider now owns 44,569 shares in the company, valued at $1,273,336.33. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, COO Daryl Gaugler sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the completion of the sale, the chief operating officer now directly owns 116,040 shares of the company's stock, valued at $3,293,215.20. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total value of $143,192.84. Following the completion of the sale, the insider now directly owns 44,569 shares of the company's stock, valued at $1,273,336.33. The disclosure for this sale can be found here. Insiders have sold a total of 22,095 shares of company stock worth $621,118 over the last 90 days. Insiders own 6.40% of the company's stock. </p><h2>Pacira BioSciences Trading Up 2.5 %</h2><p>Shares of PCRX stock opened at $21.26 on Friday. Pacira BioSciences, Inc. has a 12 month low of $19.34 and a 12 month high of $40.16. The company has a quick ratio of 4.78, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. The business's 50 day moving average is $25.03 and its two-hundred day moving average is $27.83. The company has a market cap of $980.72 million, a PE ratio of 14.87 and a beta of 0.88. </p><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $167.12 million for the quarter, compared to analyst estimates of $165.43 million. Equities analysts predict that Pacira BioSciences, Inc. will post 2.13 EPS for the current year. </p><h2>Pacira BioSciences Company Profile</h2> (Free Report)<p>Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Pacira BioSciences</li><li>Why Are These Companies Considered Blue Chips?</li><li>Hims &amp; Hers Stock Falls on DexCom Fears: Analysts Predict Rally</li><li>What Does Downgrade Mean in Investing?</li><li>Snap's Stock Plummets on Q2 Revenue Guidance Shortfall</li><li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li><li>Intel Loses a Quarter of Its Value After Horrible Earnings Report</li></ul><p><strong>Want to see what other hedge funds are holding PCRX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Rogan and Carlson Warning: Beware the Digital Currency Menace <span><span>(From Priority Gold)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3"/></p><h2>Should you invest $1,000 in Pacira BioSciences right now?</h2><p>Before you consider Pacira BioSciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p><p>While Pacira BioSciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

PCRX

<p>Price T Rowe Associates Inc. MD reduces its position in Pacira BioSciences by 17.8% in Q1. Other hedge funds also bought and sold shares of the company. Wall Street analysts forecast growth with an average target price of $41.44. Insiders have sold a total of 22,095 shares of company stock worth $621,118 in the last 90 days.</p>

Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Reduced by Price T Rowe Associates Inc. MD